Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality
IgG-based anti-cancer therapies have achieved promising clinical outcomes, but, especially for patients with solid tumors, response rates vary. IgE antibodies promote distinct immune responses compared to IgG and have shown anti-tumoral pre-clinical activity and preliminary efficacy and safety profi...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Taylor & Francis Group
2025-12-01
|
| Rangatū: | mAbs |
| Ngā marau: | |
| Urunga tuihono: | https://www.tandfonline.com/doi/10.1080/19420862.2025.2502673 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|